ASCIDIAN THERAPEUTICS
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.
ASCIDIAN THERAPEUTICS
Industry:
Biotechnology Genetics Medical Therapeutics
Founded:
2020-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.ascidian-tx.com
Total Employee:
11+
Status:
Active
Total Funding:
90 M USD
Technology used in webpage:
HSTS CrUX Dataset Amazon Virginia Region CrUX Top 10m CloudFront Ruby On Rails Token Ruby On Rails HCaptcha Out Dated Browser Onehub
Similar Organizations
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
TruMe Labs
TruMe Labs is a biotechnology research firm that focuses on the discovery of biological age.
Current Employees Featured
Jay Barth Chief Medical Officer @ Ascidian Therapeutics
Chief Medical Officer
2023-02-01
Romesh Subramanian President and CEO @ Ascidian Therapeutics
President and CEO
2022-09-01
Michael Ehlers Founder, President, and Chief Executive Officer @ Ascidian Therapeutics
Founder, President, and Chief Executive Officer
2023-11-01
Founder
Investors List
Apple Tree Partners
Apple Tree Partners investment in Series A - Ascidian Therapeutics
Apple Tree Partners
Apple Tree Partners investment in Series A - Ascidian Therapeutics
Apple Tree Partners
Apple Tree Partners investment in Seed Round - Ascidian Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2023-03-20 | Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.ascidian-tx.com Semrush global rank: 1.78 M Semrush visits lastest month: 12.64 K
- Host name: 47.119.215.35.bc.googleusercontent.com
- IP address: 35.215.119.47
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Ascidian Therapeutics"
Ascidian Life | Ascidian Therapeutics
Ascidian life – A collaborative ecosystem At Ascidian Therapeutics, we are grounded in our vision to translate discoveries into life-changing medicines for patients. Everyone on the Ascidian …See details»
Ascidian Therapeutics Strengthens Leadership Team
Neurological targets. The per-target agreement enables Ascidian to pursue additional internal and collaborative programs within neurology and other therapeutic areas. For more information, …See details»
Ascidian Therapeutics - Crunchbase Company Profile
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at …See details»
Ascidian Therapeutics, Inc.
Nov 1, 2024 Explore Ascidian Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 37 news, Disease Domain:Nervous System Diseases, …See details»
Ascidian Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Ascidian Therapeutics, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
Ascidian Therapeutics Launches to Rewrite RNA - Retinal …
A current list of the Ascidian leadership team and Board of Directors can be seen at ascidian-tx.com. About ATP Founded in 1999, ATP is a leader in life sciences venture capital, with …See details»
Orphanet: Ascidian Therapeutics, Inc.
Ascidian Therapeutics, Inc. 80 Guest Street; 4th Floor. 2135 BOSTON . UNITED STATES. Phone 1: outreach@ascidian-tx.com Institution's website Contacts. Professionals: ASCIDIAN …See details»
Ascidian Therapeutics - Craft
See insights on Ascidian Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Ascidian Therapeutics - Overview, News & Similar companies
Ascidian Therapeutics contact info: Phone number: (860) 908-6924 Website: www.ascidian-tx.com What does Ascidian Therapeutics do? Ascidian Therapeutics was founded to rewrite …See details»
Ascidian Therapeutics - Company Profile & Staff Directory
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, …See details»
Ascidian Therapeutics - Company Profile - Tracxn
Dec 27, 2024 Ascidian Therapeutics - Developer of RNA therapeutics to treat genetic diseases. Raised a total funding of $90M over 2 rounds from 1 investor. ... Email ID: *****@ascidian …See details»
Patients & Care Partners | Ascidian Therapeutics
Ascidian’s approach has the potential to treat patients with one dose of an RNA exon editor. Initial Area of Focus: Stargardt Disease Stargardt disease, the most common inherited retinal …See details»
Ascidian Company Profile 2025: Valuation, Funding & Investors
Ascidian General Information Description. Operator of a biotechnology company intended to design exon-editing RNA therapeutics to target the underlying causes of disease. The …See details»
Ascidian Therapeutics - Products, Competitors, Financials, …
About Ascidian Therapeutics. Ascidian Therapeutics is a biopharmaceutical company that works on RNA therapeutics. The company specializes in RNA exon editing, a technique designed to …See details»
Ascidian Therapeutics - VentureRadar
Auto Analyst Score: 56 | ascidian-tx.com. VentureRadar Popularity. High. VentureRadar Popularity: High. The popularity score combines profile views, clicks and the number of times …See details»
Ascidian Therapeutics - Work in biotech
Ascidian Therapeutics is creating gene therapies that replace exons via selective splicing of pre-mRNA. The technology is called RNA exon editing. A designer RNA is used to replace …See details»
Current Openings at Ascidian Therapeutics - Pharma Fan
We are seeking a VP of Regulatory Affairs, reporting to our Chief Medical Officer, to play a lead role in building out our Regulatory organization. You will be responsible for all regulatory …See details»
Texas border town wins $13M grant for environment work - The …
5 days ago Presidio, northwest of Big Bend National Park, will get dedicated green spaces along bike lanes and pedestrian streets, plant thousands of native trees and establish a high-school …See details»
IND Cleared for First RNA Exon Editor Therapy, Trial to ... - CGTliveâ„¢
Feb 15, 2024 The FDA has cleared Ascidian Therapeutics’ investigational new drug application for ACDN-01, permitting evaluation of the RNA exon editor therapy in a phase 1 trial in people with Stargardt disease. 1 "This open IND for ACDN-01 by the FDA – the first regulator to have cleared ACDN-01 for clinical development – represents an important milestone for Ascidian …See details»
Vision | Ascidian Therapeutics
Ascidian Therapeutics is a biotechnology company developing exon-editing RNA therapeutics to target the underlying causes of disease. By harnessing the RNA splicing machinery of a cell …See details»